Potential of heparin and nafamostat combination therapy for COVID‐19
Tang et al recently reported that, in COVID-19 infections caused by the novel coronavirus
(SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who …
(SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who …
[引用][C] Potential of heparin and nafamostat combination therapy for COVID‐19
H Asakura, H Ogawa - Journal of Thrombosis and Haemostasis, 2020 - Wiley Online Library
Tang et al recently reported that, in COVID-19 infections caused by the novel coronavirus
(SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who …
(SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who …
[PDF][PDF] Potential of Heparin and Nafamostat Combination Therapy for COVID-19
H Asakura, H Ogawa - sah.org.ar
Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19
infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy …
infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy …
[PDF][PDF] Potential of Heparin and Nafamostat Combination Therapy for COVID-19
H Asakura, H Ogawa - sah.org.ar
Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19
infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy …
infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy …
[引用][C] Potential of heparin and nafamostat combination therapy for COVID‐19
H Asakura, H Ogawa - Journal of Thrombosis and Haemostasis, 2020 - cir.nii.ac.jp
Potential of heparin and nafamostat combination therapy for COVID‐19 | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Potential of heparin and nafamostat combination therapy for COVID-19.
H Asakura, H Ogawa - Journal of Thrombosis and Haemostasis …, 2020 - europepmc.org
1. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of the working group on …
Assessment) score to describe organ dysfunction/failure. On behalf of the working group on …
Potential of heparin and nafamostat combination therapy for COVID‐19
H Asakura, H Ogawa - Journal of Thrombosis and Haemostasis, 2020 - ncbi.nlm.nih.gov
1. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of the working group on …
Assessment) score to describe organ dysfunction/failure. On behalf of the working group on …
[引用][C] Potential of heparin and nafamostat combination therapy for COVID-19
H Asakura, H Ogawa - Journal of thrombosis and …, 2020 - pubmed.ncbi.nlm.nih.gov
Potential of heparin and nafamostat combination therapy for COVID-19 Potential of heparin
and nafamostat combination therapy for COVID-19 J Thromb Haemost. 2020 Jun;18(6):1521-1522 …
and nafamostat combination therapy for COVID-19 J Thromb Haemost. 2020 Jun;18(6):1521-1522 …